Diagnostic Criteria for Lupus Anticoagulant Syndrome (Antiphospholipid Syndrome)
Diagnosis of antiphospholipid syndrome requires both clinical manifestations (thrombosis or pregnancy morbidity) AND persistent laboratory evidence of antiphospholipid antibodies, specifically lupus anticoagulant (LA), anticardiolipin (aCL), or anti-β2-glycoprotein I (aβ2GPI) antibodies confirmed on two separate occasions at least 12 weeks apart. 1
Clinical Criteria
You must document at least ONE of the following:
Thrombotic Events
- Arterial thrombosis in young patients (<50 years)
- Venous thromboembolism (VTE) that is unprovoked in young patients
- Thrombosis at unusual sites (cerebral, mesenteric, portal vein)
- Any thrombosis in patients with autoimmune diseases (SLE, rheumatoid arthritis, autoimmune thrombocytopenia, autoimmune hemolytic anemia) 2
Pregnancy Morbidity
- Late pregnancy loss (≥10 weeks gestation)
- Recurrent spontaneous early pregnancy loss (<10 weeks)
- Premature birth due to severe preeclampsia, eclampsia, or placental insufficiency 2
Laboratory Criteria
You must perform lupus anticoagulant testing using TWO different assays based on different principles 1:
Primary Testing Algorithm
- First-line test: dilute Russell's viper venom time (dRVVT)
- Second-line test: LA-sensitive aPTT (low phospholipids with silica activator)
- LA is positive if either test is positive 2
Testing Methodology (Critical Steps)
Each positive screening test requires:
- Mixing study (1:1 patient plasma to pooled normal plasma, no preincubation)
- Confirmatory test with increased phospholipid concentration
- LA confirmed when: prolonged screening test + non-correction on mixing + correction with excess phospholipids 1, 2
Additional Antibody Testing
Measure by ELISA only 1:
- Anticardiolipin antibodies (IgG and IgM)
- Anti-β2-glycoprotein I antibodies (IgG and IgM)
- Moderate titer: ≥40 Units
- High titer: ≥80 Units 1
Confirmation Requirements
Critical timing rule: Repeat ALL positive tests after minimum 12 weeks (but ideally before 5 years) to confirm persistence 2
Pre-Test Probability Stratification
HIGH probability (test these patients):
- Unprovoked VTE in patients <50 years
- Arterial thrombosis in young patients
- Thrombosis at unusual sites
- Late pregnancy loss
- Any thrombosis/pregnancy morbidity with autoimmune disease 2
MODERATE probability:
- Incidentally prolonged aPTT in asymptomatic patients
- Recurrent early pregnancy loss
- Provoked VTE in young patients 2
LOW probability (discourage testing):
- VTE or arterial thrombosis in elderly patients
- Asymptomatic screening 2
Critical Pitfalls to Avoid
Sample collection errors destroy test validity:
- Collect blood in 0.109 M sodium citrate (9:1 ratio)
- Double centrifugation mandatory (2000g for 15 min, then >2500g for 10 min) to ensure platelet-poor plasma
- If testing delayed, freeze plasma quickly and thaw at 37°C 2
Anticoagulant interference:
- Ideally test before starting anticoagulation or after sufficient discontinuation period
- Vitamin K antagonists cause false negatives—interpret as "absent with comment on potential false negative" 1
- Direct oral anticoagulants interfere with testing 1
Risk Stratification After Diagnosis
Triple-positive patients (LA + aCL + aβ2GPI) have highest thrombotic risk and require most aggressive management 1
Single LA-positive patients have lower risk than triple-positive but still require anticoagulation after thrombotic events 1
Key Distinction: Classification vs. Clinical Diagnosis
The 2023 ACR/EULAR classification criteria are strict for research homogeneity, while clinical diagnosis should be broader to optimize patient management—you can diagnose and treat APS patients who don't meet classification criteria if clinical suspicion is high 1